Aurinia Pharmaceuticals presents LUPKYNIS data at EULAR 2024, showing its safety and effectiveness in treating lupus nephritis, with triple therapy improving outcomes compared to dual therapy.
Aurinia Pharmaceuticals presents data at EULAR 2024, reinforcing LUPKYNIS' safety & effectiveness in treating adult patients with active lupus nephritis (LN). A propensity analysis suggests a triple therapy regimen with LUPKYNIS, lower-dose MMF, and low-dose steroids results in greater reductions in proteinuria, reduced steroid exposure, and comparable adverse event rates compared to dual therapy.
June 05, 2024
4 Articles